Calsenilin/DREAM/KChIP3, a neuronal Ca 21 -binding protein, has multifunctions in nucleus and cytosol. Here, we identified CLN3 as a calsenilin-binding partner whose mutation or deletion is observed in Batten disease. In vitro binding and immunoprecipitation assays show that calsenilin interacts with the C-terminal region of CLN3 and the increase of Ca 21 concentration in vitro and in cells causes significant dissociation of calsenilin from CLN3. Ectopic expression of CLN3 or its deletion mutant containing only the C-terminus (153 -438) and capable of binding to calsenilin suppresses thapsigargin or A23187-induced death of neuronal cells. In contrast, CLN3 deletion mutant containing the N-terminus (1-153) or (1-263), which is frequently found in Batten disease, induces the perturbation of Ca 21 transient and fails to inhibit the cell death. In addition, the expression of calsenilin is increased in the brain tissues of CLN3 knock-out mice and SH-SY5Y/CLN3 knockdown cells. Down-regulation of CLN3 expression sensitizes SH-SY5Y cells to thapsigargin or A23187. However, additional decrease of calsenilin expression rescues the sensitivity of SH-SY5Y/CLN3 knock-down cells to Ca 21 -mediated cell death. These results suggest that the vulnerability of CLN3 knock-out or CLN3 deletion (1 -153)-expressing neuronal cells to Ca 21 -induced cell death may be mediated by calsenilin.
INTRODUCTION
Calsenilin/DREAM/KChIP3 (hereafter referred to as calsenilin) was identified as a Ca 2þ -sensor that binds to the C-terminus of presenilin-1 and -2 (1) , that serves as a transcription repressor known as downstream regulatory element antagonist modulator (2) , and that binds to the A-type voltagegated potassium channel (3) . Calsenilin contains four EF-hands at its C-terminus for calcium-binding and binds to DNA in a calcium-dependent manner (1, 2) . Thus, calsenilin is believed to transduce and regulate diverse calcium-mediated signals. Calsenilin also exhibits pro-apoptotic activity in neuronal culture system (4) . The increased expression of calsenilin was suggested to be required for cell death in neuronal cells following exposure to Ab 42 (5) and sensitizes neuronal cells to serum deprivation or Ca 2þ -induced cell death (6) . g-secretase inhibitors, DAPT and compound E, suppress calsenilin-mediated death (7) . Moreover, the phosphorylation of calsenilin at Ser63 by casein kinase I regulates its cleavage by caspase 3 during apoptosis (8 -10) . While expressional regulation of calsenilin is observed in the brains of Alzheimer's disease patients (5, 10) and of epilepsy patients (11) , a role of calsenilin in human diseases is not well understood yet.
CLN3 is a transmembrane protein that is localized in lysosome/endosome (12 -15) . Mutation or deletion of CLN3 gene results in pathologic intracellular inclusions in many cell types including cortical neurons (16) and at last causes Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), also called Juvenile Batten disease (12) . Juvenile form of Batten disease is an autosomal recessive and the age of onset is usually 4-7 years, followed by visual failure. Clinical features of Batten disease are seizures, blindness and cognitive decline, leading to death at the age of 20 years (12, 17, 18 16, No. 3 317-326 doi:10.1093/hmg/ddl466 Advance Access published on December 22, 2006 and GABAnergic neurons (19 -21) . CLN3
Dex7/8 knock-in mice exhibit not only recessively inherited degenerative changes in retina, cerebral cortex and cerebellum, but also neurological deficits and premature death (22) . Neuronal death, loss of photoreceptor cells and the accumulation of lipopigments in lysosomes are representative pathology of JNCL (23, 24) . CLN3 was also shown to regulate cell growth and caspasedependent or -independent cell death operative in neurodegeneration and tumorigenesis (25 -28) . Up-regulation of CLN3 expression increases growth rate of NT2 cells and is observed in a number of cell lines and solid human colon cancer (26, 28) . Down-regulation of CLN3 expression increases apoptosis in some human cancer cells (28) . These observations show an important role of CLN3 in cell death, which may be associated with Batten disease. However, molecular mechanism of such anti-apoptotic activity of CLN3 is not well elucidated.
In this study, we isolated CLN3 as a protein interacting with calsenilin using yeast two-hybrid assay. Calsenilin binds to CLN3 that correlates the ability of CLN3 to suppress Ca 2þ -mediated cell death. Increased expression of calsenilin in CLN3 knock-down cells mediates Ca 2þ -induced neuronal cell death, providing a molecular basis for the cytoprotective activity of CLN3.
RESULTS

Calsenilin binds to the C-terminus of CLN3
In an attempt to identify calsenilin-interacting proteins, we screened the human fetal brain cDNA library using full-length calsenilin as bait for yeast two-hybrid assay. From 10 millions of yeast transformants, we have isolated three putative positive clones including CLN3, calmodulin2 and EST (accession number AC079447). In a yeast two-hybrid assay, calsenilin interacted with the C-terminus (amino acid residue 385 -438) of CLN3 (data not shown). In vitro GST-pull down assay showed that CLN3 interacts with GST-calsenilin but not with GST (Fig. 1A) . The radio-labeled CLN3 pulled down by the GST-calsenilin represents 5% of input. The endogenous interaction of CLN3 and calsenilin was then examined in SH-SY5Y human neuroblastoma cells and the brains of wild-type mice and CLN3 knock-out mice. Co-immunoprecipitation assay using CLN3 antibody showed that calsenilin was detected in the immunoprecipitates containing CLN3, indicating that CLN3 interacts with calsenilin in cells (Fig. 1B and C) . Calsenilin antibody did not crossreact with other KChIPs (Supplementary Material, Fig. S1 ) and the other lysosomal glycoprotein, lgp120, did not interact with calsenilin ( Supplementary Material Fig. S2 ). We were unable to demonstrate the interaction by reverse immunoprecipitation analysis because the molecular weight of CLN3 overlaps with the heavy chain of immunoglobulin. In addition, ectopic expression of CLN3 shows aggregated and vesicular structure, whereas calsenilin distributes in cytosol with dots ( Fig. 1D, upper panel) . However, co-expression of CLN3 with calsenilin induced an apparent change in the subcellular localization of calsenilin, showing the localization pattern of calsenilin is similar to that of CLN3 (Fig. 1D, lower panel) .
To determine the calsenilin-binding region of CLN3, we generated several deletion mutants tagged with HA epitope (Fig. 2A) . Two of such CLN3 deletion mutants, CLN3-D1-HA (1 -153) and CLN3-D2-HA (1 -263), are mostly found as truncated forms in Batten disease patients. The [
35 S]-labeled deletion mutants of CLN3 were evaluated for their abilities to bind to calsenilin in vitro (Fig. 2B) . CLN3-D1-HA (1 -153) and CLN3-D2-HA (1 -263) mutants lacking the C-terminus failed to bind to calsenilin, whereas CLN3-D3-HA (153 -438) mutant lacking the N-terminus bound to calsenilin (Fig. 2B ). CLN3-D4-HA (314 -438) was not labeled by in vitro translation. Intracellular interaction was examined after transfection with HA-tagged CLN3 deletion and calsenilin (Fig. 2C) . Western blot analysis following immunoprecipitation showed that CLN3-D3-HA (153 -438), but not CLN3-D1-HA (1 -153) and CLN3-D2-HA (1 -263), formed protein complexes with calsenilin in cells, consistent with the results of in vitro binding assay. 
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Human Molecular Genetics, 2007, Vol. 16, No. 3 Also, CLN3-D4-HA (314 -438) interacted with calsenilin. These results suggest that CLN3 interacts with calsenilin through its C-terminal region spanning residues 314-438.
The C-terminal region of CLN3 inhibits Ca
-mediated cell death
To examine the ability of each CLN3 deletion mutant to affect cell death, we generated SH-SY5Y cells stably expressing wild-type CLN3 (SH-SY5Y/CLN3-#4) or its deletion (SH-SY5Y/CLN3-D1-#4, SH-SY5Y/CLN3-D2-#2, SH-SY5Y/ CLN3-D3-#1). We have selected mixed and single clones of CLN3 cells expressing different levels of exogenous CLN3 (Fig. 3) . Overexpression of wild-type CLN3, but not other lysosomal membrane glycoprotein (lgp120) (Supplementary Material, Fig. S3 ), suppressed cell death triggered by thapsigargin, an ER Ca 2þ -ATPase inhibitor or A23187, a Ca 2þ ionophore ( Fig. 3A and B), consistent with the previous reports (25, 26) . Thapsigargin and A23187 are known to increase cytosolic concentration of free Ca 2þ and induce cell death (29) . The cytoprotective activities of CLN3 stable cells are proportional to the expression level of CLN3. SH-SY5Y/CLN3-D3-#1 cells expressing the C-terminal region of CLN3 were also resistant to cell death triggered by thapsigargin or A23187 ( Fig. 3G and H) . In contrast, SH-SY5Y/CLN3-D1-#4 and SH-SY5Y/CLN3-D2-#2 cells expressing the N-terminal regions of CLN3 were susceptible to Ca 2þ -induced cell death and rather sensitized to thapsigargin or A23187 ( Fig. 3C-F) . These results indicate that the cytoprotective activity of CLN3 resides in the C-terminal region spanning residues 153 -438.
We then generated SH-SY5Y stable cell lines (SH-SY5Y/ CLN3-AS-#3) expressing the reduced amounts of CLN3 using anti-sense cDNA. Reduced expressions of CLN3 were confirmed by western blot analysis (Fig. 4A, upper (30) and even induces cell death of sensitive cells (31) . Compared to SH-SY5Y/pcDNA control cells (Fig. 5A ), ATP-induced Ca 2þ transients significantly decreased in SH-SY5Y/CLN3 cells ( Fig. 5B and C) . In contrast, ATP-induced Ca 2þ transients did not decline but maintained higher level until late time points in SH-SY5Y/CLN3-AS cells ( Fig. 5D and E). We performed similar experiments with the mixed populations of SH-SY5Y cells expressing CLN3 deletion mutant. Whereas SH-SY5Y/CLN3-D3-Mix (N-terminal deletion mutant) cells exhibited similar Ca 2þ transient with SH-SY5Y/CLN3 cells (Fig. 5H) , expression of CLN3-D1 or CLN3-D2 sustained ATP-induced intracellular calcium level high ( Fig. 5F and G), similar to that of CLN3 knock-down cells. In addition, compared to SH-SY5Y/ pcDNA and SH-SY5Y/CLN3 cells, basal levels of cellular Ca 2þ increased by 57 + 10.5% (P , 0.05, n ¼ 3) in SH-SY5Y/CLN3-D1, SH-SY5Y/CLN3-D2 and SH-SY5Y/ CLN3-AS cells ( Fig. 5D -G) . These results show that in contrast to CLN3 and CLN3-D3, CLN3 knock-down and ectopic expression of CLN3 mutant lack in their ability to bind to calsenilin and to suppress cell death sustain [Ca 2þ ] i high, suggesting the presence of a correlation of cell death-regulating and calsenilin-binding abilities of CLN3 with the activity to modulate the intracellular calcium mobilization.
Presence of Ca 21 reduces protein -protein interaction between calsenilin and CLN3
As calsenilin is a Ca 2þ -binding protein containing four EF hands, we next examined whether Ca 2þ affects the binding of calsenilin to CLN3. In vitro GST-pull down assay showed that the presence of Ca 2þ in the reaction buffer decreases the interaction of calsenilin with CLN3; the interaction was significantly reduced by 50 mM Ca 2þ and abrogated by higher concentrations of Ca 2þ (Fig. 6A) . Calcium-dependent intracellular interaction of calsenilin with CLN3 was also evident as examined with immunoprecipitation analysis. Compared to control, treatment of HEK293 cells with thapsigargin for 24 h significantly decreased the amounts of calsenilin detected in the immunocomplexes isolated by HA antibody (Fig. 6B) . The effects of intracellular calcium rise on the co-localization of calsenilin and CLN3 were further examined in a single cell level. Treatment with thapsigargin disrupted co-localization of calsenilin and CLN3 by 48 + 6.2% (P , 0.001, n ¼ 3) at 24 h (Fig. 6C) . Subcellular localization of calsenilin was detected in diffused cytosol, which is distinct with that of CLN3 (data not shown). Previous study also showed a distinct subcellular localization of calsenilin by the elevation of intracellular calcium (32) . These results suggest that intracellular increase of calcium level may disrupt the protein-protein interaction between calsenilin and CLN3.
Calsenilin contributes to Ca 21 -mediated cell death in CLN3 knock-down cells
We then addressed whether calsenilin plays a role in Ca 2þ -mediated death of SH-SY5Y/CLN3-AS-#3 cells. Ectopic expression of calsenilin siRNA in SH-SY5Y/ CLN3-AS-#3 cells decreased the expression of calsenilin to the control level (pcDNA) as examined with western blot analysis (Fig. 7C) . Down-regulation of calsenilin expression desensitized SH-SY5Y/CLN3-AS-#3 cells to A23187 or thapsigargin-induced death ( Fig. 7A and B) ; SH-SY5Y/ CLN3-AS-#3 cells showing similar expression level of calsenilin with control cells are as sensitive to A23187 or thapsigargin-induced cell death as control cells. Also, overexpression of calsenilin further increased death of SH-SY5Y/ CLN3-AS-#3 cells (Fig. 7D) . We then examined the expression level of calsenilin in CLN3-overexpressing cells and CLN3 knock-out cells (Fig. 8) . Calsenilin level of SH-SY5Y/CLN3-#4 cells expressing more CLN3 was down-regulated by 45 + 8.2% (P , 0.05, n ¼ 3) compared to control cells ( Fig. 8A and B) . Also, calsenilin level in the brains of CLN3 knock-out mice increased by 54 + 9.9% (P , 0.05, n ¼ 3) compared to wildtype mice (Fig. 8C and D) . However, KChIP2 and actin did not show any significant changes in CLN3 knock-out mice. These results suggest that the expression level of calsenilin may be negatively regulated by CLN3.
DISCUSSION
In culture and mice model, calsenilin is believed to contribute to the pathogenesis of human disease, including regulation of Ab 42 production, cell death and pain (33, 34) . Here, we provide several lines of evidence that susceptibility of CLN3 knock-down cells to Ca 2þ -induced cell death is at least mediated by calsenilin. (i) CLN3 binds to calsenilin through its C-terminus; (ii) Like CLN3, the C-terminus of CLN3 protects cells from cell death; (iii) CLN3 regulates intracellular free calcium and ATP-induced Ca 2þ transient through its C-terminus; (iv) CLN3 negatively regulates cellular level of calsenilin; (v) Sensitization of CLN3 knock-down cells to death is rescued by additional reduction of calsenilin level; (vi) CLN3 suppresses calsenilin-induced cell death 
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Human Molecular Genetics, 2007, Vol. 16, No. 3 (data not shown). Our observations that the C-terminus of CLN3 exhibits cytoprotective activity and binds to calsenilin may provide an explanation for the loss-of-function of CLN3 deletion mutants lacking C-terminus found in Batten disease.
Most Batten disease patients have shorter CLN3 protein than normal. (http://www.ucl.ac.uk/ncl/cln3.shtml). The most abundant deletion mutant of CLN3 is a truncated protein generated by the deletion of the C-terminal region spanning residues 154-438 and the introduction of 28 amino acids (12) . In contrast to wild-type CLN3 and its deletion mutant lacking N-terminus, the C-terminal deletion mutants of CLN3 lose their cytoprotective activity and rather sensitize SH-SY5Y cells to Ca 2þ -mediated cell death. Truncated CLN3 may accumulate in the ER of BHK cells (14) and primary cultured neuronal cells (35) , showing defect in trafficking out of ER. Such accumulation of CLN3 mutants in ER may dysregulate calcium signal and induce cellular stress. Thus, the increase of cytosolic free calcium or calcium perturbation triggered by CLN3 deletion mutants, such as CLN3-D1 and CLN3-D2, may generate cellular stress, in turn leading to malfunction of the affected neurons and to sensitization of the sensitive cells to Ca 2þ -mediated cell death for long-term period. The functions of CLN3 are believed to be associated with lysosomal event, including pH regulation (36,37) and transporting arginine (38, 39) , while in human model JNCL fibroblast cells exhibit normal intracellular pH and elevated lysosomal pH (40) . There are two dileucine motifs and MX9G motifs essential for targeting lysosome in the C-terminus of CLN3 spanning residues 253-438 (15) . In addition, highly conserved amino acids across species are located in 291 VYFAE 295 and 330 VFASRSSL 337 , which may play a role in the regulation of cell growth and apoptosis (25, 26) . Recently, CLN3 was also proposed to have a role in autophagy and autophagic cell death (27, 41) , where lysosomal event is important for the maturation of autophagic vacuole. We also observed autophagic vacuole formation in CLN3 knock-down cells or cells expressing CLN3 mutant lacking the C-terminus, CLN3-D1 and CLN3-D2 (data not shown). These results reveal that the ability of CLN3 to regulate cell death seems to overlap with that of autophagic vacuole formation. Thus, in the brain tissues of JNCL patients and CLN3
Dex7/8 knock-in mice, loss of CLN3 function may be associated with the deposits of autofluorescent inclusion bodies and fingerprint structures exhibited within the CA2/ CA3 hippocampal pyramidal cell layer and cortex (22, 42) . However, whether other CLN3 mutants containing amino 
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acid substitution share similar activity with CLN3 deletion mutant remains to be further characterized. Although it is not known yet how CLN3 destabilizes or decreases calsenilin, calsenilin is apparently accumulated in the brains of CLN3 knock-out mice and CLN3 knock-down cell lines. Inversely, calsenilin may regulate the cellular function of CLN3, such as cellular trafficking including endocytosis (43) . In addition, Hook1 and CLN5 were reported to bind to CLN3 (43, 44) . Hook1 was recently identified as a microtubule-binding protein and may play a role in membrane-trafficking events (45) . CLN5 knock-out mice showed similar phenotype as CLN3-deficient mice, such as loss of vision and neurons (46) . Thus, calsenilin may also affect the CLN3-mediated endocytosis and neuronal loss. The current model is that intracellular increase of Ca 2þ concentration under pathologic conditions may cause the dissociation of calsenilin from CLN3. Our observation that relatively high level of Ca 2þ is required for such in vitro dissociation implies that additional cellular factor(s) may be needed for more efficient regulation of the intracellular dissociation.
In summary, we found that CLN3 binds to calsenilin and suppresses neuronal cell death mediated by calsenilin and dysregulation of intracellular Ca 2þ . Calsenilin contributes to the increased sensitivity of CLN3 knock-down cells to cell death, providing a new insight into a role of calsenilin and CLN3 in the pathogenic neuronal cell death.
MATERIALS AND METHODS
Yeast two-hybrid assay
Calsenilin was fused in-frame to the LexA DNA-binding domain of pLexA (pLexA-calsenilin). A human fetal brain cDNA library (3.5 Â 10 6 independent clones) in pB42AD (Clontech) was screened as described in the manufacturer's protocol. S. cerevisiae EGY48 harboring the b-galactosidase reporter plasmid p8op-lacZ was co-transformed with pB42AD-cDNA library and pLexA-calsenilin. Positive clones were identified by growth in a medium lacking leucine, and b-galactosidase activity from 1 Â 10 7 independent co-transformants. The cDNA inserts in the positive Whole brains extracts were prepared from CLN3 knock-out mice (CLN3 2 /2) and age-matched control mice (Wt), and separated by SDS-PAGE for western blotting using calsenilin antibody. Actin and KChIP2 were used as internal controls (C). Calsenilin level was quantitated by densitometric analysis. Calsenilin signal in the control mice (Wt) was taken as 100 (D). Bars indicate mean values +SD (P , 0.05, n ¼ 3).
Human Molecular Genetics, 2007, Vol. 16, No. 3 323 plasmids were sequenced with the pB42AD-forward (5 0 -ccagcctcttgctgagtggagatg-3 0 ) primer.
Antibody production
GST-calsenilin fusion protein was purified from Escherichia coli BL21(DE3) with Glutathione Sepharose 4B (Amersham Pharmacia Biotech) and injected into a rabbit, following standard immunization procedures. Calsenilin antibody was purified by calsenilin protein affinity chromatography. The rabbit anti-CLN3 antibody (Q-438) was kindly provided by M. Bennett (University of Iowa, USA).
Plasmid construction
Mammalian expression plasmids, pCLN3 and pCLN3-AS, were constructed by subcloning cDNAs into BamHI/EcoRI and EcoRI/BamHI sites of pcDNA3. 0 corresponding to human calsenilin cDNA 514-532) was generated by annealing two complementary oligoribonucleotides containing the calsenilin sequence as an inverted repeat, separated by a 9-nucleotide-long hairpin region and inserted to BglII/ HindIII site of pSUPER (Oligo Engine).
Cell culture and DNA transfection SH-SY5Y and HEK293 cells were grown in Dulbecco's Modified Eagles Medium (DMEM) (Life Technologies Inc.) supplemented with 10% fetal bovine serum (FBS). Cells were transfected for 24 h with appropriate vector using LipofectAMINE reagent (GIBCO BRL) and selected with G418 (1 mg/ml) for 2 weeks to generate mixed populations (SH-SY5Y/CLN3-Mix, SH-SY5Y/CLN3-AS-Mix, SH-SY5Y/ CLN3-D1-Mix, SH-SY5Y/CLN3-D2-Mix and SH-SY5Y/ CLN3-D3-Mix). Single cell was then separated by the limited dilution and further cultivated to form stable cell clones (SH-SY5Y/pcDNA, SH-SY5Y/CLN3-#4, SH-SY5Y/CLN 3-AS-#3, SH-SY5Y/CLN3-D1-#4, SH-SY5Y/CLN3-D2-#2 and SH-SY5Y/CLN3-D3-#1). Expression levels of CLN3 were examined with western blotting.
Live/Dead cell assay
Cells were loaded with fluorescent dyes calcein-AM (0.5 mM) and ethidium homodimer (0.5 mM) for 15 min at 378C (Live/ Dead assay, Molecular Probes) and then visualized under fluorescence microscope (Olympus). Percentage of viable cells (normalized to control) was calculated as ratios [(numbers of live cells/total cells) Â 100]. All data are expressed as mean values + SD. Significance of differences between groups was assessed by Student's paired t test. For trypan blue staining, cells were harvested and resuspended in 1 : 1 mixture of 2% trypan blue dye (Sigma) and 1Â phosphate-buffered saline (PBS).
Calcium imaging
Cells were seeded overnight in 96-well plates (Greiner) with density of 7500 -10000 cells/well and incubated with the Ca 4) , 300 mM NaCl, 1% Triton X-100, 0.1% BSA and protease inhibitors], and cell extracts were incubated with GST-fusion protein for in vitro binding assay. Beads were recovered and then washed with the binding buffer or lysis buffer A several times and the bound proteins were subjected to SDS-PAGE.
Whole brain extracts
Flash frozen whole brains of 7-month-old wild-type control mice 129S6/SvEv and homozygous CLN3 knock-out mice on a 129S6/SvEv background were kindly provided by D. Pearce (University of Rochester, USA). Tissue extracts were prepared using an Ultra-Turex T8 homogenizer (IKA Labortechnik) at 8000 r.p.m./stroke for 3Â5 strokes in ice-cold buffer containing 0.32 M sucrose, 10 mM KH 2 PO 4 , 1 mM EDTA, 20 mM leupeptin, 1 mM pepstatin and 0.5 mM phenylmethylsulphonyl fluoride (pH 7.0). Tissue debris was removed by centrifugation at 800g for 5 min at 48C and supernatant was analyzed by western blotting or stored at 2808C until further use.
Immunoprecipitation analysis
SH-SY5Y cells were lyzed for 40 min in ice-cold lysis buffer A. Mouse brain extracts prepared from age-matched wild-type mice and CLN3 knock-out mice were diluted to 0.5% in lysis 
Statistical analysis
Results comparing three or more samples were analyzed using ANOVA and Bonferroni tests, or two samples were analyzed by t-test. Only P-values ,0.05 were considered significant. Statistical analysis was performed using SigmaPlot program.
